Search Results

You are looking at 91 - 100 of 386 items for :

  • pituitary tumour x
  • Refine by Access: Content accessible to me x
Clear All
Free access

Marc Lacroix

the natural history of tumours, and that a direct haematogenous dissemination route is likely to exist that bypasses the lymphogenous one, strongly supports the search for techniques and tumour markers able to unambiguously identify disseminated tumour

Free access

Maria Grazia Vizioli, Patricia A Possik, Eva Tarantino, Katrin Meissl, Maria Grazia Borrello, Claudia Miranda, Maria Chiara Anania, Sonia Pagliardini, Ettore Seregni, Marco A Pierotti, Silvana Pilotti, Daniel S Peeper, and Angela Greco

Introduction Thyroid tumours represent the most common endocrine malignancy; the majority originate from thyroid follicular cells and include differentiated follicular thyroid carcinoma (FTC), papillary thyroid carcinoma (PTC), poorly differentiated

Free access

Krystallenia I Alexandraki, Ariadni Spyroglou, Stylianos Kykalos, Kosmas Daskalakis, Georgios Kyriakopoulos, Georgios C Sotiropoulos, Gregory A Kaltsas, and Ashley B Grossman

Introduction Neuroendocrine neoplasms (NENs) are tumours which are relatively rare but have shown an ongoing increase in their annual age-adjusted incidence, from 1.09/100,000 persons in 1973 to 6.98/100,000 persons in 2012, according to the

Free access

Elizabeth Grubbs, Daniel Halperin, Steven G Waguespack, and Robert F Gagel

/paraganglioma, pituitary adenomas, and parathyroid tumours. The association of multiple endocrine neoplasms was first recognized after the publication of case reports and small series throughout the first half of the 20th century. However, it was not until the post

Free access

Toru Tateno, Tae Nakano-Tateno, Shereen Ezzat, and Sylvia L Asa

Introduction Pituitary tumors are common, with increasing prevalences being reported ( Ezzat et al. 2004 , Daly et al. 2006 , Fernandez et al. 2009 , Fontana & Gaillard 2009 , Tjornstrand et al. 2014 , Agustsson et al. 2015

Restricted access

Mirela Diana Ilie, Alexandre Vasiljevic, Emmanuel Jouanneau, and Gérald Raverot

:// ) 30867568 Burman P Lamb L McCormack A 2020 Temozolomide therapy for aggressive pituitary tumours-current understanding and future perspectives . Reviews in Endocrine and Metabolic Disorders 21 263 – 276 . ( https

Free access

Annunziata Di Domenico, Tabea Wiedmer, Ilaria Marinoni, and Aurel Perren

disease. Multiple endocrine neoplasia type 1 has high penetrance, over 90% by age 40 years, and it is found in 1–10 per 100,000 individuals. MEN1 patients present with tumours in the parathyroid glands (95%), the anterior pituitary (20–40%), in the

Free access

Ioannis Ilias, Anju Sahdev, Rodney H Reznek, Ashley B Grossman, and Karel Pacak

Introduction The endocrine oncologist frequently has to assess adrenal tumours, and many problems may arise in defining whether lesions are primary to the adrenal or represent other tissue, they are benign or malignant and they are

Free access

M Fuertes, M Sapochnik, L Tedesco, S Senin, A Attorresi, P Ajler, G Carrizo, A Cervio, G Sevlever, J J Bonfiglio, G K Stalla, and E Arzt

.1016/0092-8674(94)90396-4 ) 7923371 10.1016/0092-8674(94)90396-4 Clayton RN Farrell WE 2004 Pituitary tumour clonality revisited . Frontiers of Hormone Research 32 186 – 204 . 15281347 Chesnokova V Zonis S Rubinek T Yu R Ben-Shlomo A Kovacs K Wawrowsky K Melmed S 2007

Free access

Fateme Salehi, Kalman Kovacs, Bernd W Scheithauer, Ricardo V Lloyd, and Michael Cusimano

tumor development . Endocrinology 147 4781 – 4791 . Filippella M Galland F Kujas M Young J Faggiano A Lombardi G Colao A Meduri G Chanson P 2006 Pituitary tumour transforming gene (PTTG) expression correlates with the